To evaluate the efficacy and safety of latanoprost compared with other glaucoma medications in the treatment of chronic angle-closure glaucoma (CACG) and to provide the basis for clinical medication.
Major literature databases were searched for randomized controlled trials (RCT) involving latanoprost among patients with CACG. Primary outcome measures were absolute changes in intraocular pressure (IOP) and incidence of ocular adverse events. Statistical analyses included the calculation of standardized mean difference (SMD) and relative risk (RR). The statistical analysis was performed using STATA version 12.0 software.
Ten RCT involving 1096 patients were included in this meta-analysis. Analysis showed that latanoprost was not significantly different from other glaucoma medications in reducing IOP (SMD = 0.29, 95% confidence interval [CI] –0.02 to 0.59, p=0.069). Further subgroup analysis revealed that latanoprost was superior compared with timolol (SMD = 0.64, 95% CI 0.46 to 0.82, p<0.001) and marginally inferior to travoprost and bimatoprost (SMD = –0.19, 95% CI –0.35 to –0.02, p = 0.026). As for conjunctival hyperemia, latanoprost caused a higher proportion than timolol (RR = 2.36, 95% CI 1.27 to 4.37, p = 0.007). However, latanoprost was associated with lower incidence of conjunctival hyperemia (RR = 0.42, 95% CI 0.30 to 0.59, p<0.001), and with fewer occurrence of other ocular side effects (excluding conjunctival hyperemia) than travoprost and bimatoprost (RR = 0.61, 95% CI 0.48 to 0.78, p<0.001).
Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG.
Eur J Ophthalmol 2015; 25(1): 18 - 26
Article Type: ORIGINAL RESEARCH ARTICLE
Article Subject: Glaucoma
AuthorsJingjing Li, Xiaoti Lin, Minbin Yu
- • Accepted on 17/06/2014
- • Available online on 08/07/2014
- • Published in print on 11/11/2014
This article is available as full text PDF.
- Li, Jingjing [PubMed] [Google Scholar] 1, 2, *
- Lin, Xiaoti [PubMed] [Google Scholar] 3, 4, *
- Yu, Minbin [PubMed] [Google Scholar] 1, * Corresponding Author (email@example.com)
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou - People’s Republic of China
Department of Ophthalmology, Xiangyang Central Hospital, Teaching Hospital of Medical College of Hubei University of Arts and Science, Xiangyang, Hubei Province - People’s Republic of China
Department of Breast Oncology, Sun Yat-sen University Cancer Center, Guangzhou - People’s Republic of China
Department of Surgery, Fujian Provincial Tumor Hospital, Teaching Hospital of Fujian Medical University, Fuzhou - People’s Republic of China
These authors contributed equally to this manuscript